New developments in flavivirus vaccines with special attention to yellow fever

Current Opinion in Infectious Diseases

Volumn 18, Issue 5, 2005, Pages 387-394

  Pugachev, Konstantin V ^a   Guirakhoo, Farshad ^a   Monath, Thomas P ^a  

^a Acambis   (United States)

Author keywords

Flavivirus; Prevention; Resurgence; Safety; Vaccine; Yellow fever

Indexed keywords

CHIMERIVAX; DENGUE VACCINE; DNA VACCINE; FLAVIMUNE; INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SA 14142; STAMARIL; SUBUNIT VACCINE; VIRUS VACCINE; YELLOW FEVER VACCINE;

CLINICAL TRIAL; DEMYELINATING DISEASE; DENGUE; DISEASE TRANSMISSION; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; ENCEPHALITIS; EPIDEMIC ENCEPHALITIS; GUILLAIN BARRE SYNDROME; HEPATITIS; HUMAN; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOGENETICS; PUBLIC HEALTH SERVICE; REVIEW; TICK BORNE ENCEPHALITIS; VACCINATION; VACCINE PRODUCTION; VECTOR CONTROL; VIRUS INFECTION; WEST NILE FLAVIVIRUS; YELLOW FEVER; YELLOW FEVER FLAVIVIRUS;

EID: 25144523093     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qco.0000178823.28585.ad     Document Type: Review

References (75)

1. Burke DS, Monath TP. Flaviviruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields, Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 1043-1126.
2. Lindenbach BD, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields, Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. pp. 991-1041.
3. Gubler DJ. The changing epidemiology of yellow fever and dengue, 1900 to 2003: full circle? Comp Immunol Microbiol Infect Dis 2004; 27:319-330. This is an excellent review of the current yellow fever and dengue epidemiological situation and factors contributing to resurgence of these viruses.
4. Monath TP. Yellow fever vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 4th ed. Philadelphia: Saunders; 2004. pp. 1095-1176. This is a recently updated in-depth review of yellow fever and the 17D vaccines.
5. WHO. Yellow fever vaccine. Weekly Epidemiol Rec 2003; 78:349-359.
6. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1:11-20.
7. Robertson SE, Hull BP, Tomori O, et al. Yellow fever: a decade of reemergence. JAMA 1996; 276:1157-1162.
8. Barrett AD. Current status of the Arilvax yellow fever vaccine. Expert Rev Vaccines 2004; 3:413-420. This article provides a short summary of World Health Organization criteria for 17D vaccine manufacturing and information on vaccine efficacy and safety, particularly as exemplified by three recent phase III clinical trials of Arilvax conducted by Acambis in USA, UK and Peru.
9. Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005; 72:189-197. This report describes data from the most recent phase III trial comparing Arilvax and YF-VAX.
10. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66:533-541.
11. Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51:1-11.
12. Barwick RS, Marfin AA, Cetron MS. Yellow fever vaccine-associated disease. In: Scheld WM, Murray BE, Hughes JM, editors. Emerging infections. 6th ed. Washington DC: ASM Press; 2004. pp. 25-34.
13. Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination: United States, 2001-2002. MMWR 2002;51:989-993.
14. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004; 22:2103-2105.
15. Struchiner CJ, Luz PM, Dourado I, et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004; 132:939-946. This excellent paper summarizes developments in the yellow fever epidemiological situation in Brazil during 1991-2001, changes in vaccination strategies influenced by observation of adverse events, and recalculation of fatality risk for yellow fever 17DD vaccination.
16. Marfin A, Eidex RB, Monath TP. Yellow fever. In: Guerrant R, Walker D, Weller P, editors. Tropical infectious diseases: principles, pathogens, practice. 2nd ed. Philadelphia: Churchill Livingstone (in press).
17. Filippis AM, Nogueira RM, Jabor AV, et al. Isolation and characterization of wild type yellow fever virus in cases temporally associated with 17DD vaccination during an outbreak of yellow fever in Brazil. Vaccine 2004; 22:1073-1078. This report emphasizes the need to verify sequence identity of virus isolates from cases of suspected yellow fever post-vaccination adverse events.
18. Lawrence GL, Burgess MA, Kass RB. Age-related risk of adverse events following yellow fever vaccination in Australia. Commun Dis Intell 2004; 28:244-248. This paper confirms earlier US estimates of a higher frequency of yellow fever vaccine-associate disease in the elderly based on Australian surveillance data.
19. Martin M, Weld LH, Tsai TF, et al. Advanced age is a risk factor for illness temporally associated with yellow fever vaccination. Emerg Infect Dis 2001; 7:945-951.
20. Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 2001; 358:98-104.
21. Galler R, Pugachev KV, Santos CL, et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001; 290:309-319.
22. Rodrigues SG, da Rosa AP, Galler R, et al. Yellow fever virus isolated from a fatal post vaccination event: an experimental comparative study with the 17DD vaccine strain in the Syrian hamster (Mesocricetus auratus). Rev Soc Bras Med Trop 2004; 37 (Suppl 2):69-74. This paper contains useful information for yellow fever vaccine researchers on replication of yellow fever 17DD virus in hamster tissues.
23. Brinton MA, Perelygin AA. Genetic resistance to flaviviruses. Adv Virus Res 2003; 60:43-85.
24. Barwick RE. History of thymoma and yellow fever vaccination. Lancet 2004; 364:936.
25. Rice CM, Grakoui A, Galler R, Chambers TJ. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol 1989; 1:285-296.
26. Bredenbeek PJ, Kooi EA, Lindenbach B, et al. A stable full-length yellow fever virus cDNA clone and the role of conserved RNA elements in flavivirus replication. J Gen Virol 2003; 84:1261-1268.
27. Chang GJ, Kuno G, Purdy DE, Davis BS. Recent advancement in flavivirus vaccine development. Expert Rev Vaccines 2004; 3:199-220. This is the most recent review of traditional and novel vaccines, with emphasis on naked DNA candidates.
28. Pugachev KV, Guirakhoo F, Trent DW, Monath TP. Traditional and novel approaches to flavivirus vaccines. Int J Parasitol 2003; 33:567-582.
29. Kinney RM, Huang CY. Development of new vaccines against dengue fever and Japanese encephalitis. Intervirology 2001; 44:176-197.
30. Van Epps HL. Broadening the horizons for yellow fever: new uses for an old vaccine. J Exp Med 2005; 201:165-168. This provides a brief overview of recent research on using 17D virus as a vector for vaccines against pathogens outside Flaviviridae.
31. Tao D, Barba-Spaeth G, Rai U, et al. Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model. J Exp Med 2005; 201:201-209. This paper describes a new example of using a recombinant 17D virus as a malaria vaccine with demonstration of efficacy in a mouse challenge model.
32. Bonaldo MC, Garratt RC, Caufour PS, et al. Surface expression of an immunodominant malaria protein B cell epitope by yellow fever virus. J Mol Biol 2002; 315:873-385.
33. McAllister A, Arbetman AE, Mandl S, et al. Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases. J Virol 2000; 74:9197-9205.
34. Jones CT, Patkar CG, Kuhn RJ. Construction and applications of yellow fever virus replicons. Virology 2005; 331:247-259. This paper describes construction of yellow fever 17D replicon vectors that can express reporter genes and are packaged into viral particles.
35. Molenkamp R, Kooi EA, Lucassen MA, et al. Yellow fever virus replicons as an expression system for hepatitis C virus structural proteins. J Virol 2003; 77:1644-1648.
36. Westaway EG, Mackenzie JM, Khromykh AA. Kunjin RNA replication and applications of Kunjin replicons. Adv Virus Res 2003; 59:99-140.
37. Mackenzie JS, Gubler DJ, Petersen LR. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 2004; 10 (12 Suppl):S98-S109. This is an excellent review of the current Japanese encephalitis, West Nile virus and dengue epidemiological situation illustrating the ease with which mosquito-borne viruses can colonize new areas and environments.
38. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988; 239:476-481.
39. Kurane I, Ennis FE. Immunity and immunopathology in dengue virus infections. Semin Immunol 1992; 4:121-127.
40. Halstead SB, Tsai TF. Japanese encephalitis vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 4th ed. Philadelphia: Saunders; 2004. pp. 919-958. This is an in depth review of Japanese encephalitis vaccines, the disease and recent epidemiology.
41. Oransky I. Gates Foundation gives 27 million US dollars to fight Japanese encephalitis. Lancet Neurol 2004; 3:74.
42. Jacobson J, Sivalenka S. Japanese encephalitis globally and in India. Indian J Public Health 2004; 48:49-56. This paper provides excellent examples of inadequate policies for prevention of Japanese encephalitis in India and throughout Asia. Sixty-eight percent of children born in poorest Asian countries are at risk of infection.
43. Centers for Disease Control and Prevention (CDC). Japanese encephalitis in a U.S. traveler returning from Thailand, 2004. MMWR Morb Mortal Wkly Rep 2005; 54:123-125. The report is a reminder to physicians on the need to consider Japanese encephalitis vaccinations for persons traveling to Japanese encephalitis endemic countries.
44. Heinz FX, Kunz C. Tick-borne encephalitis and the impact of vaccination. Arch Virol Suppl 2004; 18:201-205. This is a short overview of TBE pathogenesis, disease distribution, and the benefit of vaccination using available inactivated vaccines.
45. Marth E, Kleinhappl B, Jelovcan S. Stimulation of the immune system by different TBE-virus vaccines. Int J Med Microbiol 2004; 293 (Suppl 37):139-144.
46. Zent O, Plentz A, Schwarz TF, et al. TBE booster immunization according to the rapid immunization schedule: are 3-year booster intervals really necessary? Vaccine 2004; 23:312-315.
47. Zent O, Schwarz TF, Plentz A, et al. TBE booster immunization in adults: first experience with a new tick-borne encephalitis (TBE) vaccine, free of protein-derived stabilizer. Int J Med Microbiol 2004; 293 (Suppl 37): 134-138.
48. Hall RA, Khromykh AA. West Nile virus vaccines. Expert Opin Biol Ther 2004; 4:1295-1305. This is a comprehensive review of West Nile virus human and veterinary vaccine research on the development of inactivated, chimeric, live attenuated, naked DNA and purified subunit candidates.
49. Lai CJ, Monath TP. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis. Adv Virus Res 2003; 61:469-509.
50. Putnak R, Porter K, Schmaljohn C. DNA vaccines for flaviviruses. Adv Virus Res 2003; 61:445-468.
51. Saluzzo JF. Empirically derived live-attenuated vaccines against dengue and Japanese encephalitis. Adv Virus Res 2003; 61:419-443.
52. Eckels KH, Putnak R. Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines. Adv Virus Res 2003; 61:395-418.
53. Gritsun TS, Nuttall PA, Gould EA. Tick-borne flaviviruses. Adv Virus Res 2003; 61:317-371.
54. Putnak R, Barvir DA, Burrous JM, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174:1176-1184.
55. Sabchareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004; 23:99-109. This presents the latest illustration of improved immunogenicity of a tetravalent dengue vaccine (Mahidol) through formulation adjustment and the use of three inoculations. Reactogenicity in children indicates further improvement.
56. Yamshchikov G, Borisevich V, Seregin A, et al. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live, WN vaccine development. Virology 2004; 330:304-312.
57. Pugachev KV, Monath TP, Guirakhoo F. Chimeric vaccines against Japanese encephalitis, dengue, and West Nile. In: Levine MM, Kaper JB, Rappuoli R, et al., editors. New generation vaccines. 3d ed. New York Basel: Marcel Dekker; 2004. pp. 559-571. The review provides comprehensive ChimeriVax history, description of the molecular approach, and test results in animal models (mice, monkeys, mosquitoes) and data from first clinical trials.
58. Johnson BW, Chambers TV, Crabtree MB, et al. Analysis of the replication kinetics of the ChimeriVax-DEN 1, 2, 3, 4 tetravalent virus mixture in Aedes aegypti by real-time reverse transcriptase-polymerase chain reaction. Am J Trop Med Hyg 2004; 70:89-97. This excellent paper demonstrates that ChimeriVax vaccines cannot replicate efficiently in mosquitoes, and thus the possibility of uncontrolled dissemination is very little.
59. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis(ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003; 188:1213-1230.
60. Guirakhoo F, Pugachev K, Zhang Z. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78:4761-4775. This paper describes a first tetravalent dengue vaccine that was shown to provide solid protection of non-human primates against all four serotypes of dengue.
61. Arroyo J, Miller C, Catalan J, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78:12497-12507. This paper describes the construction and data from testing in mice and monkeys of ChimeriVax-WN, the first West Nile virus vaccine to recently enter human clinical trials.
62. Blaney JE Jr, Hanson CT, Firestone CY, et al. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 2004; 71:811-821. The construction of novel chimeric dengue-4/dengue-3 vaccine candidates is described.
63. Hanley KA, Manlucu LR, Manipon GG, et al. Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 2004; 22:3440-3448. This paper describes work to improve safety of the attenuated dengue-4 backbone.
64. Whitehead SS, Hanley KA, Blaney JE Jr, et al. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 2003; 21:4307-4316.
65. Durbin AP, Whitehead SS, McArthur J, et al. rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis 2005; 191:710-718. This paper describes the most recent trials of dengue-4 vaccine candidate with the delta30 mutation. The vaccine has a very low infectious dose for humans, but additional attenuation may be necessary.
66. Pletnev AG, Bray M, Hanley KA, et al. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes. J Virol 2001; 75:8259-8267.
67. Pletnev AG, Claire MS, Elkins R, et al. Molecularly engineered live-attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003; 314:190-195.
68. Men R, Bray M, Clark D, et al. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J Virol 1996; 70:3930-3937.
69. Hanley KA, Goddard LB, Gilmore LE, et al. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors. Vector Borne Zoonotic Dis 2005; 5:1-10.
70. Whitehead SS, Falgout B, Hanley KA, et al. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol 2003; 77:1653-1657.
71. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 2005; 79:5516-5528. This paper describes possible ways to attain balanced immunity using different tetravalent dengue vaccine formulations.
72. Mandl CW. Flavivirus immunization with capsid-deletion mutants: basics, benefits, and barriers. Viral Immunol 2004; 17:461-472. The most recent approach to TBE virus attenuation via specific deletions in the capsid protein C is described.
73. Kofler RM, Heinz FX, Mandl CW. A novel principle of attenuation for the development of new generation live flavivirus vaccines. Arch Virol Suppl 2004; (18):191-200. The most recent approach to TBE virus attenuation via specific deletions in the capsid protein C is described.
74. Kofler RM, Aberle JH, Aberle SW, et al. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci U S A 2004; 101:1951-1956.
75. de Souza Lopes O, Coimbra TL, de Abreu Sacchetta L, Calisher CH. Emergence of a new arbovirus disease in Brazil. I. Isolation and characterization of the etiologic agent, Rocio virus. Am J Epidemiol 1978; 107:444-449.